Goldman, professor of public policy, pharmacy and economics at USC, and Lakdawalla, professor of pharmaceutical and health economics, co-authored the commentary, published on Monday, June 19.
“In baseball, the issue of player salaries faded long ago. The talent pool is deep, stadiums are full, beer and hot dog sales are brisk, and lucrative TV contracts keep owners flush. Equilibrium has been achieved. In drug pricing, the debate remains at full throttle. The big question: How much do we need to pay today to attract the investment that will keep drug discovery alive tomorrow?”
Read more in the Wall Street Journal.